A phase II trial of single-agent cetuximab dose escalated to rash in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma

Trial Profile

A phase II trial of single-agent cetuximab dose escalated to rash in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2010

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb; ImClone Systems
  • Most Recent Events

    • 09 Nov 2008 Additional trial identifier 'CA225046' added as reported by ClinicalTrials.gov.
    • 09 Nov 2008 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 20 Jul 2007 The expected completion date for this trial is now 1 Jun 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top